Divis Laboratories - Generic API

Corporate & Background

Custom Manufacturing

Business & Products

			Generic API's

			Intermediates

			Peptide Building Blocks

			Carotenoids (Synthetic) and Nutraceuticals

			Future Generics

Facilities & Strengths

Ethics & Values

Regulatory Submissions

Investors & Financials

Locations & Contact

Our Nutraceuticals website

News & Events

	Divi's Labs earns an Income of Rs.366 crores in Q2 of FY12

	Divi's Labs earns a PBT of Rs. 130 crores for Q1 of FY12

	Divi's Labs PAT for Q4 grew by 36% to Rs.175 crores

	Divi's Labs earns an Income of Rs.313 crores for Q3 of FY11

	Divi's Labs earns an Income of Rs.265 crores in Q1

	Divi's Labs earns a PAT of Rs.129 crores for Q4

	Divi's Labs earns an Income of Rs.649 crores for 9M of FY10

	Divi's Labs earns an Income of Rs.445 crores in H1 of FY10

	Divi's Labs earns a PAT of Rs.417 for the year 2008-09 And declares 1:1 bonus

	Divi's Labs PAT for 9 months grows by 21% to Rs.309 crores

	Divi's Labs PAT for Q2 grows by 49% to Rs.135 crores

	Divi's Labs PAT for Q1 grows by 45% to Rs.94 crores

	Divi's Labs PAT for FY08 grows by 87% to Rs.348 crores

	Divi's Labs PAT for Q3 grows by 216% to Rs.99 crores

	Divi's Labs PAT for Q2 grows by 204% to Rs.91 crores

	Divi's Labs PAT for Q1 grows by 153% to Rs.65 crores

	Divi's Labs PAT for FY07 grows by 167% to Rs.186 crores

	Divi's Labs Q3 total income grows by 38% to Rs.152 crores

	Divis successful US-FDA inspection for Unit II

	Divi's Labs Q2 total income grows by 97% to Rs.165 crores.

	Divi's Labs Q1 total income grows by 142% at Rs.165 crores

	Divi's Laboratories earns a Net of Rs.19 crores on an Income of Rs.110 Crores in Q3

	Divis labs SEZs cleared

	Divis Laboratories earns a PBT of Rs.43 Crores in First-Half of FY06

	Divis Laboratories earns a total income of Rs.68 Crores in Q1 of FY06

	Divis Laboratories earns a total income of Rs.365 Crores in FY05

	Divis Laboratories earns a Net of Rs.105 Crores in Q3

	Divis Laboratories earns a PBT of Rs.45 Crores in First-Half of FY05

	Divis Laboratories earns a Net of Rs.14 Crores in Q1

Divis manufacture API's for the Generics. As a company Divis understand that sustained development is not possible without respecting to IPR. Divis takes great care to ensure that its product or processes do not infringe valid patents.

Divis is actively involved in developing alternate, patent non-infringing processes for APIs, for the inventors to manage late life cycle and leading generic drug manufacturers.

Product Name	Structure
BUPROPION Hbr
BUPROPION HCl CAS No : 31677-93-7
CAPECITABINE CAS No : 154361-50-9
CARBIDOPA CAS No : [28860-95-9]
DESLORATADINE CAS No: [100643-71-8]
DEXLANSOPRAZOLE /(R)-LANSOPRAZOLE CAS No [138530-94-6]
DEXTROMETHORPHAN BASE CAS No [125-71-3]
DEXTROMETHORPHAN HBr CAS No [6700-34-1] (monohydrate)
DILTIAZEM HCl CAS No [33286-22-5]
FEXOFENADINE CAS No [153439-40-8]
FOSPHENYTOIN SODIUM CAS No 92134-98-0
GABAPENTIN CAS No [60142-96-3]
IOPAMIDOL CAS No [60166-93-0]
IRBESARTAN CAS No [138402-11-6]
LEVETIRACETAM CAS No : 102767-28-2
LEVODOPA CAS No : 59-92-7
NABUMETONE CAS No [42924-53-8]
NAPROXEN CAS No [22204-53-1]
NAPROXEN SODIUM CAS No [26159-34-2]
NATEGLINIDE CAS No : 105816-04-4
NIACIN CAS No : 59-67-6
PHENYLEPHRINE HCl CAS No [61-76-7]
PROGUANIL HCl CAS No [637-32-1]
QUETIAPINE FUMARATE CAS No [111974-72-2]
RISEDRONATE SODIUM CAS No [115436-72-1]
SERTRALINE HCl CAS No [79559-97-0]
SIBUTRAMINE HCl CAS No [125494-59-9]
TAMSULOSIN HCl CAS No [106463-17-6]
TELMISARTAN CAS No [144701-48-4]
TRIPROLIDINE HCl CAS No [6138-79-0]
VALACYCLOVIR HCl CAS No [124832-27-5]
VALSARTAN CAS No [137862-53-4]
VENLAFAXINE HCl CAS No [99300-78-4]
VERAPAMIL HCl CAS No [152-11-4]
VIGABATRIN CAS No [60643-86-9]
ZOLPIDEM TARTRATE CAS No [99294-93-6]
Disclaimer: Products covered by valid patents are not offered for commercial use.It is the buyers responsibility to ensure the transactions do not infringe any patent rights applicable

top

Copyright © 2006, Divis Laboratories Ltd. All Rights Reserved

Web design london